Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Somatostatinoma × Sunitinib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 63 Neoplasm Metastasis 23 Kidney Neoplasms 23 Breast Neoplasms 14 Neoplasms 13 Prostatic Neoplasms 12 Urinary Bladder Neoplasms 9 Melanoma 8 Glioblastoma 8 Gastrointestinal Stromal Tumors 8 Sarcoma 7 Carcinoma, Non-Small-Cell Lung 7 Brain Neoplasms 6 Ovarian Neoplasms 5 Liver Neoplasms 5 Esophageal Neoplasms 5 Colorectal Neoplasms 5 Thyroid Neoplasms 4 Solid Tumors 4 Recurrence 4 Pancreatic Neoplasms 4 Osteosarcoma 4 Lung Neoplasms 4 Leukemia, Myeloid, Acute 4 Carcinoma, Hepatocellular 4 Adenocarcinoma 4 Uveal Melanoma 3 Thymoma 3 Stomach Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Temozolomide 3 Leucovorin 3 Fluorouracil 3 Capecitabine 3 pentetreotide 2 Bevacizumab 2 veliparib 1 vatalanib 1 regorafenib 1 palbociclib 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 dehydroftorafur 1 Thalidomide 1 Sunitinib 1 Panobinostat 1 Oxaliplatin 1 Octreotide 1 Magnetic Resonance Spectroscopy 1 Irinotecan 1 High-Energy Shock Waves 1 Everolimus 1 Doxorubicin 1 Bortezomib 1 Blood Specimen Collection 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02230176 2025-04-20

OCCLURANDOM

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡